Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 259 participants.
Also called NCT03096288
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 259 participants
- Sponsor
- Registry
-
NCT03096288
-
- Other papers using this trial's data
- Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03096288. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-03 (actual); primary completion 2020-11-02 (actual). Results posted on 2022-02-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Evolocumab
- Intervention (Other)
- Placebo
- Lead sponsor
- University of Florida
- Collaborator
- Amgen
Record details
- Record id
cardio:ct-nct03096288- Content hash
a0bb3cf77ef94bce76729be39996f35f550fd480d263067bb2280e87bce77cdc